Cancer represents a group of diseases characterized by uncontrolled cell proliferation and the ability to invade distant tissues. While not a neurodegenerative disease per se, cancer and neurodegeneration share remarkable molecular overlap, providing crucial therapeutic insights for both fields.
Cancer and neurodegenerative diseases represent opposite ends of the cellular dysregulation spectrum — one marked by excessive cell proliferation, the other by premature cell death. Yet, they share fundamental molecular mechanisms including DNA repair defects, mitochondrial dysfunction dysfunction, protein aggregation, epigenetic alterations, and metabolic reprogramming[1]. Understanding these shared pathways offers novel therapeutic strategies and reveals fundamental biology of cellular homeostasis.
The intersection of cancer biology and neurodegeneration research has emerged as a critical frontier, with several drugs originally developed for cancer showing promise in neurodegenerative conditions and vice versa[2].
The p53 tumor suppressor protein regulates cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 (the gene encoding p53) are the most common genetic alterations in human cancers[3]. Interestingly, p53 also plays a critical role in neuronal survival — wild-type p53 promotes neurite outgrowth, while mutant p53 aggregates are found in some neurodegenerative conditions[4]. The balance between p53's pro-survival and pro-apoptotic functions determines whether cells undergo neurodegeneration or transformation.
ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are central to DNA damage response. ATM deficiency causes ataxia-telangiectasia, characterized by neurodegeneration and increased cancer risk[5]. This duality exemplifies the shared biology — defective DNA repair promotes both neuronal death and malignant transformation.
Neurons are post-mitotic, having permanently exited the cell cycle. Aberrant cell cycle re-entry is a hallmark of neurodegeneration, while uncontrolled cell cycle progression defines cancer[6]. Key regulators including CDK4/6, cyclin D, RB1, and p16 are dysregulated in both conditions.
Mitochondrial defects are prevalent in both neurodegeneration (Alzheimer's, Parkinson's disease's) and cancer (Warburg effect)[7]. PGC-1α (PPARGC1A), the master regulator of mitochondrial biogenesis, is downregulated in neurodegenerative diseases and altered in many cancers. MTOR signaling integrates metabolic status with cell growth — hyperactivation occurs in many cancers, while dysregulated mTOR signaling contributes to neurodegeneration.
While the specific aggregating proteins differ (amyloid-beta and tau in Alzheimer's, alpha-synuclein in Parkinson's, p53 in some cancers), the failure of protein quality control systems is a common feature[8]. UBQLN2, VCP, and HSP70 family members are implicated in both protein aggregation diseases and cancer progression.
| Gene | Cancer Association | Neurodegeneration Link |
|---|---|---|
| TP53 | Li-Fraumeni syndrome | p53 aggregates in AD, ALS |
| PTEN | Multiple cancers | Neuronal survival, mTOR regulation |
| RB1 | Retinoblastoma | Cell cycle exit in neurons |
| ATM | ATM-deficient tumors | Ataxia-telangiectasia with neurodegeneration |
| BRCA1/2 | Breast/ovarian cancer | DNA repair in neurons |
MYC, RAS, and BCL2 family members are expressed in neurons where they regulate synaptic plasticity, memory formation, and apoptotic thresholds — functions distant from their original characterization in cancer[9].
Both cancer and neurodegeneration involve profound epigenetic changes:
The shared biology enables therapeutic repurposing:
Genetic susceptibility to both conditions can inform prevention strategies. Individuals with DNA repair syndromes (ataxia-telangiectasia, Fanconi anemia) require cancer surveillance while also being at risk for neurodegeneration.
Kuimov et al. Cancer and Neurodegeneration (2021). 2021. ↩︎
Miller et al. Linking Cancer and Neurodegeneration (2023). 2023. ↩︎
Donehower et al. TP53 in Cancer and Aging (2022). 2022. ↩︎
Jiang et al. p53 and Neurodegeneration (2023). 2023. ↩︎
McKinnon et al. ATM and DNA Damage in the Nervous System (2022). 2022. ↩︎
Herrup et al. Cell Cycle Re-entry in Neurodegeneration (2023). 2023. ↩︎
Wallace et al. Mitochondria and Cancer (2022). 2022. ↩︎
Soto et al. Protein Misfolding in Cancer and Neurodegeneration (2022). 2022. ↩︎
Coppola et al. Oncogenes in the Nervous System (2023). 2023. ↩︎
Portela et al. Epigenetic Alterations in Cancer and Neurodegeneration (2022). 2022. ↩︎
Chow et al. [CDK4/6 Inhibitors for Alzheimer's disease's Disease (2024)](https://doi.org/10.1038/s41591-024-01956-7). 2024. ↩︎